Compare ALEMBIC LTD with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC LTD vs GSK PHARMA - Comparison Results

ALEMBIC LTD     Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC LTD GSK PHARMA ALEMBIC LTD/
GSK PHARMA
 
P/E (TTM) x 74.2 32.9 225.4% View Chart
P/BV x 2.6 13.1 20.1% View Chart
Dividend Yield % 0.4 1.2 32.0%  

Financials

 ALEMBIC LTD   GSK PHARMA
EQUITY SHARE DATA
    ALEMBIC LTD
Mar-18
GSK PHARMA
Mar-19
ALEMBIC LTD/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs723,595 2.0%   
Low Rs341,253 2.7%   
Sales per share (Unadj.) Rs4.7184.7 2.5%  
Earnings per share (Unadj.) Rs6.126.3 23.2%  
Cash flow per share (Unadj.) Rs6.229.2 21.4%  
Dividends per share (Unadj.) Rs0.2020.00 1.0%  
Dividend yield (eoy) %0.40.8 45.8%  
Book value per share (Unadj.) Rs40.7126.3 32.2%  
Shares outstanding (eoy) m267.03169.40 157.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x11.313.1 85.8%   
Avg P/E ratio x8.792.2 9.4%  
P/CF ratio (eoy) x8.583.1 10.2%  
Price / Book Value ratio x1.319.2 6.8%  
Dividend payout %3.376.1 4.3%   
Avg Mkt Cap Rs m14,139410,626 3.4%   
No. of employees `000NA5.0 0.0%   
Total wages/salary Rs m2075,372 3.9%   
Avg. sales/employee Rs ThNM6,306.7-  
Avg. wages/employee Rs ThNM1,083.1-  
Avg. net profit/employee Rs ThNM898.0-  
INCOME DATA
Net Sales Rs m1,25531,281 4.0%  
Other income Rs m3701,023 36.2%   
Total revenues Rs m1,62532,304 5.0%   
Gross profit Rs m1116,009 1.8%  
Depreciation Rs m38486 7.8%   
Interest Rs m26 28.3%   
Profit before tax Rs m4426,540 6.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m0287 0.0%   
Tax Rs m242,373 1.0%   
Profit after tax Rs m1,6304,454 36.6%  
Gross profit margin %8.919.2 46.1%  
Effective tax rate %5.436.3 14.9%   
Net profit margin %129.814.2 911.9%  
BALANCE SHEET DATA
Current assets Rs m1,86720,061 9.3%   
Current liabilities Rs m59114,543 4.1%   
Net working cap to sales %101.617.6 576.2%  
Current ratio x3.21.4 228.9%  
Inventory Days Days9457 166.0%  
Debtors Days Days7414 523.0%  
Net fixed assets Rs m1,79114,343 12.5%   
Share capital Rs m5341,694 31.5%   
"Free" reserves Rs m10,32419,704 52.4%   
Net worth Rs m10,85821,398 50.7%   
Long term debt Rs m412 2,060.0%   
Total assets Rs m11,59139,113 29.6%  
Interest coverage x260.91,091.0 23.9%   
Debt to equity ratio x00 4,059.8%  
Sales to assets ratio x0.10.8 13.5%   
Return on assets %14.111.4 123.4%  
Return on equity %15.020.8 72.1%  
Return on capital %15.231.9 47.6%  
Exports to sales %1.50-   
Imports to sales %21.00-   
Exports (fob) Rs m19NA-   
Imports (cif) Rs m263NA-   
Fx inflow Rs m19534 3.6%   
Fx outflow Rs m2647,091 3.7%   
Net fx Rs m-244-6,557 3.7%   
CASH FLOW
From Operations Rs m2363,994 5.9%  
From Investments Rs m-224-1,433 15.6%  
From Financial Activity Rs m-27-3,584 0.7%  
Net Cashflow Rs m-15-1,023 1.4%  

Share Holding

Indian Promoters % 64.0 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 0.2 10.2 2.0%  
FIIs % 9.7 23.8 40.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 15.4 169.5%  
Shareholders   54,701 102,036 53.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC LTD With:   ABBOTT INDIA  JUBILANT LIFE SCIENCES  BIOCON   IPCA LABS  NATCO PHARMA  

Compare ALEMBIC LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 76 Points Lower; Telecom and Metal Stocks Witness Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their volatile day marginally lower.

Related Views on News

GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

GSK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 16.6% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 16.6% YoY). Sales on the other hand came in at Rs 8 bn (up 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

How the Modi Government is Helping My Top 7 Stocks(The 5 Minute Wrapup)

Nov 14, 2019

Recent reforms by the Modi government can give a big boost on your stocks, provided you buy the right ones.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC LTD SHARE PRICE


Nov 21, 2019 (Close)

TRACK ALEMBIC LTD

  • Track your investment in ALEMBIC LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC LTD 8-QTR ANALYSIS

COMPARE ALEMBIC LTD WITH

MARKET STATS